In the published article, there was an error in the name and abbreviation of the measure “mean corpuscular hemoglobin concentration” abbreviated to “MCHC”. It should be “mean corpuscular hemoglobin” and abbreviated to “MCH”. Throughout the text of the article, “mean corpuscular hemoglobin concentration” has been corrected to “mean corpuscular hemoglobin” and the abbreviation “MCHC” has been corrected to “MCH”.
In the published article, there was an error in the header, title and legend for Table 1 as published. “MCHC” should be written as “MCH”.
The corrected Table 1 and its legend appear below.
Table 1
| Genotype | Cases (n) | RBC ( × 1012/L) | Hb (g/L) | MCV (fL) | MCH (pg) |
|---|---|---|---|---|---|
| Normal | 5,365 | 4.36 ± 0.44 | 119.4 ± 15.2a | 82.51 ± 7.42 | 27.51 ± 3.26b |
| –α3.7/αα | 1,757 | 4.58 ± 0.44 | 119.6 ± 12.4 | 79.28 ± 3.94 | 26.16 ± 1.85 |
| –α4.2/αα | 1,674 | 4.61 ± 0.45 | 119.9 ± 11.9 | 79.25 ± 4.04 | 26.15 ± 1.94 |
| αWSα/αα | 698 | 4.54 ± 0.49 | 119.5 ± 12.8 | 79.77 ± 5.29 | 26.49 ± 2.42d |
| αCSα/αα | 59 | 4.48 ± 0.32 | 116.3 ± 8.8 | 79.34 ± 3.24 | 25.94 ± 1.47 |
| αQSα/αα | 299 | 4.85 ± 0.42 | 117.6 ± 10.3c | 74.81 ± 3.77 | 24.37 ± 1.66e |
| –SEA/αα | 1,716 | 5.20 ± 0.5 | 111.8 ± 9.8f | 67.54 ± 3.75 | 21.58 ± 1.47h |
| –α3.7/–α3.7 | 292 | 4.90 ± 0.46 | 112.1 ± 10.5f | 71.49 ± 4.0 | 22.96 ± 1.61i |
| –α3.7/–α4.2 | 526 | 4.92 ± 0.50 | 112.1 ± 10.2f | 71.10 ± 3.72 | 22.85 ± 1.43i |
| –α4.2/–α4.2 | 266 | 4.98 ± 0.51 | 112.6 ± 11.4f | 70.93 ± 3.78 | 22.82 ± 1.85i |
| αWSα/–α3.7 | 325 | 4.64 ± 0.47 | 117.2 ± 11.7g | 77.74 ± 3.92 | 25.41 ± 1.88 |
| αWSα/–α4.2 | 283 | 4.67 ± 0.43 | 117.3 ± 10.6g | 77.32 ± 4.36 | 25.15 ± 1.72 |
| αWSα/αWSα | 88 | 4.61 ± 0.49 | 119.8 ± 14.3g | 79.14 ± 4.41 | 26.21 ± 2.16 |
| αWSα/αQSα | 32 | 4.99 ± 0.47 | 117.1 ± 10.7g | 72.50 ± 2.99 | 23.47 ± 0.82j |
| αQSα/–α3.7 | 59 | 5.06 ± 0.58 | 105.1 ± 9.8 | 65.55 ± 3.93 | 21.08 ± 1.89k |
| αQSα/–α4.2 | 40 | 5.21 ± 0.55 | 105.5 ± 10.9 | 64.50 ± 3.88 | 20.59 ± 2.51k |
| –SEA/–α3.7 | 74 | 4.74 ± 0.60 | 85.53 ± 9.6 | 60.00 ± 6.40 | 18.94 ± 3.42 |
| –SEA/–α4.2 | 74 | 4.73 ± 0.49 | 87.05 ± 9.8 | 61.33 ± 6.41 | 18.75 ± 2.43 |
| –SEA/αWSα | 57 | 5.14 ± 0.50 | 108.1 ± 10.7l | 65.95 ± 4.54 | 21.06 ± 1.59l |
| βCD17(A>T)/β | 81 | 5.13 ± 0.58 | 103.2 ± 8.9 | 63.28 ± 4.04 | 20.31 ± 1.53 |
| βCD41/42(−TTCT)/β | 807 | 5.06 ± 0.60 | 102.1 ± 10.0 | 63.32 ± 3.77 | 20.36 ± 1.61 |
| βCD71/72(+A)/β | 68 | 5.03 ± 0.58 | 102.2 ± 10.6 | 63.52 ± 3.14 | 20.34 ± 1.19 |
| βIVS − II − 654(C>T)/β | 112 | 5.02 ± 0.48 | 102.1 ± 7.9 | 63.46 ± 3.29 | 20.46 ± 1.33 |
| β−28(A>G)/β | 259 | 4.93 ± 0.44 | 112.6 ± 9.3m | 70.69 ± 3.46 | 22.92 ± 1.26m |
| βCD26(GAG>AAG)/β | 40 | 4.63 ± 0.35 | 117.1 ± 8.3m | 76.08 ± 3.19 | 25.49 ± 1.52m |
The value of Hb and MCH in PW with or without thalassemia genotypes.
The value of Hb and MCH were compared among different groups. (1) aThe Hb level of Normal group was higher than those of αQSα/αα, –SEA/αα, –α3.7/–α3.7, –α3.7/–α4.2, –α4.2/–α4.2, αWSα/–α3.7, αWSα/–α4.2, αQSα/–α3.7, αQSα/–α4.2, –SEA/αWSα, –SEA/–α3.7, –SEA/–α4.2, βCD17(A>T)/β, βCD41/42(−TTCT)/β, βCD71/72(+A)/β, βIVS − II − 654(C>T)/β, and β−28(A>G)/β groups (P < 0.05); bthe MCH level of Normal group was higher than those of all other groups (P < 0.05). (2) Among α-thalassemia silent genotypes, cthe Hb level of αQSα/αα was lower than those of –α3.7/αα, –α4.2/αα, αWSα/αα (P < 0.05); dthe MCH level of αWSα/αα was higher than those of –α3.7/αα, –α4.2/αα, αQSα/αα and αCSα/αα (P < 0.05); ethe MCH level of αQSα/αα was lower than those of –α3.7/αα, –α4.2/αα, and αCSα/αα (P < 0.05). (3) Among α-thalassemia minor genotypes, fthe Hb levels of –SEA/αα, –α3.7/–α3.7, –α3.7/–α4.2, –α4.2/–α4.2 were lower than those of αWSα/–α3.7, αWSα/–α4.2, αWSα/αWSα, while was higher than those of αQSα/–α3.7 groups (P < 0.05); gthe Hb levels of αWSα/–α3.7, αWSα/–α4.2, αWSα/αWSα, αWSα/αQSα were higher than those of αQSα/–α3.7, αQSα/–α4.2 (P < 0.05); hthe MCH level of –SEA/αα was higher than that of αQSα/–α4.2, while was lower than those of –α3.7/–α3.7, –α3.7/–α4.2, –α4.2/–α4.2, αWSα/–α3.7, αWSα/–α4.2, αWSα/αWSα, αWSα/αQSα (P < 0.05); ithe MCH levels of –α3.7/–α3.7, –α3.7/–α4.2, –α4.2/–α4.2 were lower than those of αWSα/–α3.7, αWSα/–α4.2, αWSα/αWSα, while were higher than those of αQSα/–α3.7, αQSα/–α4.2 (P < 0.05); jthe MCH level of αWSα/αQSα was lower than that of αWSα/αWSα (P < 0.05); kthe MCH levels of αQSα/–α3.7, αQSα/–α4.2 were lower that those of αWSα/–α3.7, αWSα/–α4.2, αWSα/αWSα, αWSα/αQSα (P < 0.05). (4) Among the α-thalassemia intermediate genotypes, lthe Hb and MCH levels of –SEA/αWSα were lower than those of –SEA/–α3.7, and –SEA/–α4.2 (P < 0.05); (5) Among the β-thalassemia minor genotypes, mthe Hb and MCH levels of β−28(A>G)/β, βCD26(GAG>AAG)/β were higher than those of βCD17(A>T)/β, βCD41/42(−TTCT)/β, βCD71/72(+A)/β, βIVS − II − 654(C>T)/β (P < 0.05). nnumber; PW, pregnant women; RBC, red blood cell; Hb, hemoglobin; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin.
In the published article, there was an error in the legend for Table 2, “The levels of Hb and PF in APW with or without ID” as published. “=” should be written as “≥”; “PF: the PF levels in APW” should be written as “PF: the PF levels in all APW”. The corrected Table 2 and its legend appears below.
Table 2
| Genotype | HbPF < 30(g/L) | HbPF≥30(g/L) | PF*(ng/mL) | PF (ng/mL) | ||||
|---|---|---|---|---|---|---|---|---|
| Mean ±SD | n | Mean ±SD | n | t | p | Mean ±SD | Median, (P25; P75) | |
| Normal | 97.1 ± 11.0 | 160 | 102.6 ± 8.7 | 23 | 2.294 | < 0.05 | 91.91 ± 64.40a | 11.70, (8.40; 17.60) |
| –α3.7(or4.2)/αα | 98.7 ± 9.2 | 49 | 105.1 ± 4.2 | 36 | 4.275 | < 0.01 | 82.09 ± 46.62a | 18.20, (8.71; 57.80)a, c |
| αCS(orQS)α/αα | / | 2 | / | 3 | / | / | / | 32.00, (9.37; 45.30)a |
| αWSα/αα | 95.1 ± 14.6 | 14 | / | 4 | / | / | / | 13.25, (8.43, 28.33)a, c |
| αα/–SEA | 99.6 ± 7.6 | 45 | 103.7 ± 4.8 | 56 | 3.181 | < 0.01 | 96.82 ± 55.65a | 34.10, (17.10; 90.60)a, b, d |
| –α3.7(or4.2)/–α3.7(or4.2) | 98.5 ± 9.1 | 16 | 101.6 ± 7.4 | 24 | 1.196 | > 0.05 | 99.26 ± 81.13a | 38.40, (15.40; 87.40)a, b |
| αCS(orQS)α/–α3.7(or4.2) | / | 2 | 100.9 ± 4.9 | 9 | / | / | 135.90 ± 82.67 | 79.10, (30.80; 237.00)b |
| αWSα/–α3.7(or4.2) | 99.8 ± 8.2 | 16 | / | 3 | / | / | / | 13.80, (9.98; 20.90)a, c |
| αWSα/αWSα | / | 2 | / | 0 | / | / | / | / |
| αQSα/αQSα | / | 0 | / | 1 | / | / | / | / |
| –α3.7(or4.2)/–SEA | / | 0 | 88.27 ± 7.2 | 22 | / | / | 283.2 ± 131.3 | 270.90, (186.30; 353.00)b |
| αCSα/–SEA | / | 0 | / | 1 | / | / | / | / |
| αWSα/–SEA | / | 1 | 99.80 ± 5.4 | 5 | / | / | 187.6 ± 129.6 | 95.65, (70.73; 317.80)b |
| βT4/β | 94.9 ± 8.1 | 14 | 99.50 ± 6.9 | 115 | 2.325 | < 0.05 | 122.9 ± 72.71a | 95.45, (53.05; 140.90)b |
| β−28(A>G)/β | / | 2 | 103.70 ± 4.1 | 18 | / | / | 119.00 ± 75.21a | 80.15, (52.00; 188.50)b |
| βCD26(GAG>AAG)/β | / | 0 | / | 1 | / | / | / | / |
The levels of Hb and PF in APW with or without ID.
HbPF < 30: The Hb levels in APW with ID (PF < 30 ng/mL). HbPF≥30: the Hb levels in APW without ID (PF ≥ 30 ng/mL). PF*: the PF levels in APW without ID (PF ≥ 30 ng/mL). PF: the PF levels in all APW. –α3.7(or4.2)/αα, –α3.7/αα and –α4.2/αα were combined into one group. αCS(orQS)α/αα, αCSα/αα and αQSα/αα were combined into one group. –α3.7(or4.2)/–α3.7(or4.2): –α3.7/–α3.7, –α3.7/–α4.2, and –α4.2/–α4.2 were combined into one group. αCS(orQS)α/–α3.7(or4.2): αCSα/–α3.7, αCSα/–α4.2, αQSα/–α3.7, and αQSα/–α4.2 were combined into one group. αWSα/–α3.7(or4.2): αWSα/–α3.7, and αWSα/–α4.2 were combined into one group. –α3.7(or4.2)/–SEA: –α3.7/–SEA, and -α4.2/–SEA were combined into one group. βT4/β: βIVS − II − 654(C>T)/β, βCD41/42(−TTCT)/β, βCD17(A>T)/β, and βCD71/72(+A)/β were combined into one group. aP < 0.05 vs. the group of −α3.7(or4.2)/–SEA. bP < 0.05 vs. the Normal group. cP < 0.05 vs. the groups of βT4/β and β−28(A>G)/β. dP < 0.05 vs. the group of βT4/β. /: statistical analysis was performed when the sample size was greater than 5. Hb, hemoglobin; PF, plasma ferritin; APW, anemic pregnant women; ID, iron deficiency.
In the published article, there was an error. A correction has been made to the section Results, subsection “Analysis of anemia prevalence and hematological phenotype indexes in pregnant women with various thalassemia genotypes”, paragraph 1. This sentence previously stated:
“The anemia rates of αα/–SEA, –α3.7/–α3.7, –α3.7/–α4.2, and –α4.2/–α4.2 ranged from 35.96 to 37.82% (P < 0.05).”
The corrected sentence appears below:
“The anemia rates of αα/–SEA, –α3.7/–α3.7, –α3.7/–α4.2, and –α4.2/–α4.2 ranged from 35.96 to 37.82% (P > 0.05).”
A correction has been made to the section Discussion, subsection “Analysis of anemia prevalence and hematological phenotype indexes of pregnant women with various thalassemia genotypes”, paragraph 1. This sentence previously stated:
“The anemia rate among carriers of αα/–SEA, –α3.7/–α3.7, –α4.2/–α4.2, and –α3.7/–α4.2 ranged from 35.96 to 37.82% (P < 0.05), and no significant differences were observed in Hb levels among those genotypes.”
The corrected sentence appears below:
“The anemia rate among carriers of αα/–SEA, –α3.7/–α3.7, –α4.2/–α4.2, and –α3.7/–α4.2 ranged from 35.96 to 37.82% (P > 0.05), and no significant differences were observed in Hb levels among those genotypes.”
A correction has been made to the section Discussion, subsection “Prevalence of iron deficiency in anemic pregnant women with various genotypes of thalassemia”, paragraph 1. This sentence previously stated:
“Although there is no large sample, multicenter randomized controlled study that has yet confirmed the need for routine iron supplementation in PW with thalassemia minor genotypes, we suggest that the iron load of APW with β- thalassemia minor genotypes should be monitored dynamically during iron supplementation”
The corrected sentence appears below:
“Although there is no large sample, multicenter randomized controlled study that has yet confirmed the need for routine iron supplementation in PW with thalassemia minor genotypes, we suggest that the ferritin levels of APW with β- thalassemia minor genotypes should be monitored dynamically during iron supplementation”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
iron-deficiency anemia (IDA), pregnancy, prevalence, iron supplementation, thalassemia
Citation
Wang M, Zhang X, Zhao Y, Zhang Y, Lin Y, Xiao M and Li L (2023) Corrigendum: Prevalence of iron-deficiency anemia in pregnant women with various thalassemia genotypes: thoughts on iron supplementation in pregnant women with thalassemia genes. Front. Nutr. 10:1254578. doi: 10.3389/fnut.2023.1254578
Received
07 July 2023
Accepted
18 August 2023
Published
30 August 2023
Approved by
Mohamed A. Yassin, Qatar University, Qatar
Volume
10 - 2023
Updates
Copyright
© 2023 Wang, Zhang, Zhao, Zhang, Lin, Xiao and Li.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Meifang Xiao xiaomeifang2006@hotmail.comLing Li lcl115@163.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.